Lomustine
- Generic Name
- Lomustine
- Brand Names
- Ceenu, Gleostine
- Drug Type
- Small Molecule
- Chemical Formula
- C9H16ClN3O2
- CAS Number
- 13010-47-4
- Unique Ingredient Identifier
- 7BRF0Z81KG
- Background
An alkylating agent of value against both hematologic malignancies and solid tumors.
- Indication
For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
- Associated Conditions
- Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma
- Associated Therapies
- -
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- VBI Vaccines Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT03382977
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸The Valley Hospital - Neurosurgeons of New Jersey, Ridgewood, New Jersey, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 100
- Registration Number
- NCT03025893
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
🇳🇱Radboud UMC, Nijmegen, Netherlands
🇳🇱University Medical Center Groningen, Groningen, Netherlands
Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
- Conditions
- Interventions
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT03022578
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Regorafenib in Relapsed Glioblastoma
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 119
- Registration Number
- NCT02926222
- Locations
- 🇮🇹
IRCCS "Saverio de Bellis, Castellana Grotte, BA, Italy
🇮🇹Azienda Ospedaliera "G.Rummo", Benevento, BR, Italy
🇮🇹istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori, Cesena, FC, Italy
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
- Conditions
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Orbus Therapeutics, Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT02796261
- Locations
- 🇨🇦
Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷Centre Georges François Leclerc, Dijon, France
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
- Conditions
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Proximagen, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02765165
- Locations
- 🇺🇸
University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸University of Texas/MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 45
- Registration Number
- NCT02724579
- Locations
- 🇺🇸
Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States
🇺🇸Tufts Children's Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Tocagen Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT02414165
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸University of Miami, Miami, Florida, United States
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
- Conditions
- Interventions
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 266
- Registration Number
- NCT02343406
- Locations
- 🇫🇷
Hopital Pitie Salpetriere /ID# 145887, Paris, France
🇮🇹Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 140395, Milan, Italy
🇫🇷CHU-Hopital Avicenne /ID# 137910, Bobigny, Ile-de-France, France
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
- Conditions
- Interventions
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 6
- Registration Number
- NCT02212574
- Locations
- 🇺🇸
Ann and Robert H Lurie Children's Hospital of Chicago Hematology/Oncology, Chicago, Illinois, United States
🇺🇸Children's Hospital Colorado Center for Cancer & Blood Disorders, Aurora, Colorado, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.